Next Phase Newsletter

A private venture capital firm based in the US focuses on early-stage life science and healthcare opportunities that can create a meaningful impact in the industry. The firm focuses on investments in Seed to Series B stages, with initial checks typically ranging from $250k to $1.5M and potential follow-on investments. The firm prefers co-investing and usually collaborates with syndicates for its investments, rather than leading investments. However, the firm is open to speaking with companies that do not have a lead investor in place. The firm only invests within the US. 
 
The firm is primarily focused on therapeutics and medical devices and will also consider diagnostics and lab equipment. However, the firm does not invest in software or digital health. The firm is more opportunistic in subsectors and indications, remaining open to different modalities and disease areas. Within the therapeutics sector, the firm has invested in small molecule and tRNA companies, and is open to considering rare diseases. Regarding the phase of development for therapeutics, The firm considers opportunities ranging from pre-clinical to phase II. For medical devices, the firm prefers to see certain validation, particularly first-in-human data, or animal data depending on the market. The firm is open to considering all classes of medical devices. 
 
The firm does not have specific requirements on companies’ founding or management teams. The firm is open to talking to both serial and first-time entrepreneurs. As an active investor, the firm is open to considering board or observer seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm invests solely in AI-enabled software companies, focusing on cybersecurity, healthcare, vertical applications, enterprise infrastructure, biocomputation, and space and robotics. Typical check sizes are around USD $500k for U.S. companies seeking Seed rounds. Since 2010, the firm has invested in over 50 companies. 
 
In terms of healthcare, the firm invests in clinical digital health companies. The firm is not exclusive to digital health but sees AI as a key enabler. The firm would like to see companies with at least minimal revenue. 

The firm would like to see at least 2 members on the founding team that have complimentary skills: a member with healthcare experience and a technical lead with AI and software experience. The firm may take an observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with offices in US and Asia typically invests in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot. 
 
The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc. 
 
The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with offices in Europe actively invests in healthtech companies that address the global market. The firm typically invests in Seed and Series A rounds and can invest up to €5M, with additional capital reserved for follow-ons. The firm focuses on Europe-based companies. 
 
The firm is currently seeking healthtech companies that are B2B focused. The firm has invested in therapeutics, medical device, and diagnostics companies in the past. The firm prefers to invest in companies who have a commercialized product with initial revenue and traction. The firm has been opportunistic towards indication.  
 
The firm seeks to work with companies backed by an ambitious management team working on technologies with a highly scalable business model, and backed by strong IP. The firm seeks board representation in efforts to be an active partner of their portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with offices in the US looks to invest in diagnostics companies addressing gaps and answering problems present in the current market. The firm really looks to fund companies with a large market need. The firm invests exclusively in Seed to Series A rounds, with the ability for follow-on investments. The firm typically invests $1M-5M in the form of equity, with the ability to go up to $10M. The firm invests globally. 
 
The firm is solely focused on diagnostics companies. The firm is indication- and modality- agnostic, and open to all classes of diagnostics. The firm can also invest in associated data tools; however, their focus lies in diagnostics companies. The firm invests in pre-commercial companies. 
 
The firm typically co-invests. The firm likes to see management teams with diagnostic industry experience. The firm considers themselves “hands-on” investors, able to provide specific industry experience. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A group of angel investors operates with a fund model with an average check size of USD $100K – $500K. The firm will both lead deals and will follow-on as well as syndicate with other angel groups. The majority of deals fall within the Seed-Series A range. The group only invests in U.S.-based C-Corps.  
 
The firm is typically sector-agnostic in terms of technology and life science. Some members are more interested in early-stage Seed deals while others are looking for technologies that have been adequately de-risked. 
 
The firm is looking for privately-held, technology-based companies with experienced management teams that can demonstrate strong execution skills, potential for market dominance, high growth, and a sustainable competitive advantage. 

For deals where the firm would be acting as a co-investor, it is required that the round have a strong lead investor – i.e. one that actively negotiated the term sheet, represents a sizeable portion of the round, is taking an active role in the company (usually has a board seat) and has completed an internal due diligence effort and is willing to share the results of their due diligence effort with the firm members.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporation with over 100 years of history and multibillion dollar assets under management has a venture arm that invests in healthcare. The venture arm will be contributing to investments in biotech companies in Series A and later stage companies. The goal of this venture arm is to bring new biotech innovation to Saudi Arabia and the Middle Eastern regions. Initial investments will range from $3M-5M in the form of a combination of equity and cash or non-diluted equity if the company has assets that could be leveraged in Saudi Arabia, which includes performing clinical research, manufacturing, and/or commercialization. The firm is predominantly interested in innovative therapeutics, digital health, and personalized diagnostics and with a preference for companies prioritizing US FDA and/or EMA approval. For therapeutics, the firm prefers clinical stage companies. For digital health and diagnostics, the firm prefers companies that have beta tested their product/platforms. 
 
Within therapeutics, the firm is focused on cell and gene therapy in Phase 2 and/or moving into Phase 3, with expectations for accelerated approvals. There are several indications of interest, including rare diseases, oncology, neurodegeneration, immunology, metabolic diseases, therapeutic vaccines, and regenerative therapeutics. Within digital health and diagnostics, the firm is primarily interested in technologies that are enterprise solutions, provider prescribed, personalized medicine or drug discovery engines. 
 
The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the Gulf and Middle Eastern regions. Relocation is not required, however, a carveout or partnership at least in Saudi Arabia and other Gulf countries is necessary. The firm does not require a board seat but does prefer an observer seat after equity investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.